|
Mar 4
|
Akero Therapeutics Announces Proposed Public Offering of Common Stock
|
|
Mar 4
|
Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment
|
|
Mar 4
|
Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
|
|
Mar 4
|
Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market
|
|
Mar 4
|
UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients
|
|
Mar 4
|
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
|
|
Mar 4
|
Akero strengthens MASH drug’s case with new study data
|
|
Jan 3
|
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 18
|
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
|
|
Dec 13
|
Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ...
|
|
Dec 5
|
12 Most Promising Stocks to Buy According to Hedge Funds
|
|
Nov 15
|
Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results
|
|
Nov 13
|
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Nov 10
|
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
|
|
Nov 8
|
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
|
|
Sep 14
|
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
|
|
Jul 11
|
Infinity Pharma (INFI) Stock Up on Advancing Cancer Study
|
|
Jul 10
|
Viking Therapeutics (VKTX) Surges 64% Year to Date: Here's Why
|
|
Jul 10
|
Sotherly Hotels' (SOHO) Q2 Operating Trend Reflects Solid Demand
|
|
Jul 10
|
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
|